Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Leukemia and Lymphoma

• Publication date

  2012-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428194.2011.623257PMID 21942285PMCID PMC5571758
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

  2011cited by this paper
• Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

  2011cited by this paper
• Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: Implications for minimal residual disease detection

  2010cited by this paper
• Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.

  2010cited by this paper
• Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell‐related disorders

  2010cited by this paper
• Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders

  2010cited by this paper
• Extramedullary plasmacytoma are characterized by a ‘myeloma‐like’ immunophenotype and genotype and occult bone marrow involvement

  2010cited by this paper
• Review: extramedullary disease in multiple myeloma.

  2009cited by this paper
• The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome

  2009cited by this paper
• Plasma cell myeloma.

  2009cited by this paper
• Instability of immunophenotype in plasma cell myeloma.

  2008cited by this paper
• Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

  2008cited by this paper
• New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

  2007cited by this paper
• Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.

  2004cited by this paper
• Review of 1027 patients with newly diagnosed multiple myeloma.

  2003cited by this paper
• Newly diagnosed multiple myeloma

  2002cited by this paper
• CD38: a new paradigm in lymphocyte activation and signal transduction

  1998cited by this paper
• Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule.

  1994cited by this paper

• CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy

  2025cites this paper
• p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain)

  2022cites this paper
• Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.

  2021cites this paper
• Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

  2020cites this paper
• CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

  2018cites this paper
• Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies

  2018cites this paper
• CARs and other T cell therapies for MM: The clinical experience.

  2018cites this paper
• Immunologic approaches for the treatment of multiple myeloma.

  2017cites this paper
• RETRACTED ARTICLE: Immuntherapie des multiplen Myeloms

  2017cites this paper
• Immunotherapies targeting CD38 in Multiple Myeloma

  2016cites this paper